The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Drugging the Cancer Chaperone HSP90: Combinatorial Therapeutic Exploitation of Oncogene Addiction and Tumor Stress
Abstract
The molecular chaperone HSP90 has emerged as an exciting target for cancer treatment. We review the potential advantages of HSP90 inhibitors, particularly the simultaneous combinatorial depletion of multiple oncogenic “client” proteins, leading to blockade of many cancer‐causing pathways and the antagonism of all of the hallmark pathological traits of malignancy. Cancer selectivity is achieved by exploiting cancer “dependencies,” including oncogene addiction and the stressed state of malignant cells. The multiple downstream effects of HSP90 inhibitors should make the development of resistance more difficult than with agents having more restricted effects. We review the various classes of HSP90 inhibitor that have been developed, including the natural products geldanamycin and radicicol and also the purine scaffold and pyrazole/isoxazole class of synthetic small molecule inhibitors. A first‐in‐class HSP90 drug, the geldanamycin analog 17‐AAG, has provided proof of concept for HSP90 inhibition in patients at well tolerated doses and therapeutic activity has been seen. Other inhibitors show promise in preclinical and clinical development. Opportunities and challenges for HSP90 inhibitors are discussed, including use in combination with other agents. Most of the current HSP90 inhibitors act by blocking the essential nucleotide binding and ATPase activity required for chaperone function. Potential new approaches are discussed, for example, interference with cochaperone binding and function in the superchaperone complex. Biomarkers for use with HSP90 inhibitors are described. We stress how basic and translational research has been mutually beneficial and indicate future directions to enhance our understanding of molecular chaperones and their exploitation in cancer and other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sain, N., Krishnan, B., Ormerod, M. G., Rienzo, A. D., Liu, W. M., Kaye, S. B., Workman, P., & Jackman, A. L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0445 · Cited by 92
Self-citationRetractedThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Self-citationHSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270
A new puffing pattern induced by temperature shock and DNP in drosophila
Ritossa, F. (1962) · Experientia · doi:10.1007/bf02172188 · Cited by 2,068
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
Self-citationStructure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
Heat shock proteins in cancer: chaperones of tumorigenesis
Calderwood, S. K., Khaleque, M. A., Sawyer, D. B., & Ciocca, D. R. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.01.006 · Cited by 957
Zhao, R., Davey, M., Hsu, Y.-C., Kaplanek, P., Tong, A., Parsons, A. B., Krogan, N., Cagney, G., Mai, D., Greenblatt, J., et al. (2005) · Cell · doi:10.1016/j.cell.2004.12.024 · Cited by 819
Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
Self-citationDickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642
Self-citationHieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S. M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.005 · Cited by 624
Hsp90 Cochaperone Aha1 Downregulation Rescues Misfolding of CFTR in Cystic Fibrosis
Wang, X., Venable, J., LaPointe, P., Hutt, D. M., Koulov, A. V., Coppinger, J., Gurkan, C., Kellner, W., Matteson, J., Plutner, H., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.043 · Cited by 601
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
Supko, J. G., Hickman, R. L., Grever, M. R., & Malspeis, L. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689048 · Cited by 510
Marcu, M. G., Chadli, A., Bouhouche, I., Catelli, M., & Neckers, L. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003701200 · Cited by 502
Self-citationBanerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 488
Self-citationShe, Q.-B., Solit, D. B., Ye, Q., O’Reilly, K. E., Lobo, J., & Rosen, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 421
Self-citationAn Acetylation Site in the Middle Domain of Hsp90 Regulates Chaperone Function
Scroggins, B. T., Robzyk, K., Wang, D., Marcu, M. G., Tsutsumi, S., Beebe, K., Cotter, R. J., Felts, S., Toft, D., Karnitz, L., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.12.008 · Cited by 413
Self-citationNovobiocin and Related Coumarins and Depletion of Heat Shock Protein 90-Dependent Signaling Proteins
Marcu, M. G., Schulte, T. W., & Neckers, L. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.242 · Cited by 405
Self-citationNew approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Self-citationTargeting multiple signal transduction pathways through inhibition of Hsp90
Zhang, H., & Burrows, F. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0549-9 · Cited by 377
Self-citationDiscovery of the heat shock response
Ritossa, F. (1996) · Cell Stress & Chaperones · doi:10.1379/1466-1268(1996)001<0097:dothsr>2.3.co;2 · Cited by 377
Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228
Yu, X. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.7.504 · Cited by 360
High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer
Pick, E., Kluger, Y., Giltnane, J. M., Moeder, C., Camp, R. L., Rimm, D. L., & Kluger, H. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4511 · Cited by 356
Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1940 · Cited by 350
Self-citationPhase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Goetz, M. P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A. A., Sloan, J., Atherton, P., Vasile, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.119 · Cited by 336
Role of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel hERG
Ficker, E., Dennis, A. T., Wang, L., & Brown, A. M. (2003) · Circulation Research · doi:10.1161/01.res.0000079028.31393.15 · Cited by 323
Inhibitors of the HSP90 Molecular Chaperone: Current Status
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)95009-x · Cited by 310
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., & Rosen, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609973103 · Cited by 308
Self-citationChiosis, G., Timaul, M. N., Lucas, B., Munster, P. N., Zheng, F. F., Sepp-Lorenzino, L., & Rosen, N. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00015-1 · Cited by 288
Self-citationTargeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol
Sharma, S. V., Agatsuma, T., & Nakano, H. (1998) · Oncogene · doi:10.1038/sj.onc.1201790 · Cited by 277
Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms
Wright, L., Barril, X., Dymock, B., Sheridan, L., Surgenor, A., Beswick, M., Drysdale, M., Collier, A., Massey, A., Davies, N., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.033 · Cited by 268
Self-citationShimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 259
da Rocha Dias, S., Friedlos, F., Light, Y., Springer, C., Workman, P., & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2632 · Cited by 246
Self-citationCombinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
Workman, P. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.08.032 · Cited by 242
Self-citationNovobiocin: Redesigning a DNA Gyrase Inhibitor for Selective Inhibition of Hsp90
Burlison, J. A., Neckers, L., Smith, A. B., Maxwell, A., & Blagg, B. S. J. (2006) · Journal of the American Chemical Society · doi:10.1021/ja065793p · Cited by 242
Self-citationSydor, J. R., Normant, E., Pien, C. S., Porter, J. R., Ge, J., Grenier, L., Pak, R. H., Ali, J. A., Dembski, M. S., Hudak, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608372103 · Cited by 231
Matthews, R. C., Rigg, G., Hodgetts, S., Carter, T., Chapman, C., Gregory, C., Illidge, C., & Burnie, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2208-2216.2003 · Cited by 231
Hsp90: the vulnerable chaperone
Chiosis, G., Vilenchik, M., Kim, J., & Solit, D. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03245-3 · Cited by 229
Dymock, B. W., Barril, X., Brough, P. A., Cansfield, J. E., Massey, A., McDonald, E., Hubbard, R. E., Surgenor, A., Roughley, S. D., Webb, P., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050355z · Cited by 227
Self-citationCheung, K.-M. J., Matthews, T. P., James, K., Rowlands, M. G., Boxall, K. J., Sharp, S. Y., Maloney, A., Roe, S. M., Prodromou, C., Pearl, L. H., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.046 · Cited by 219
Self-citationXu, W., & Neckers, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2966 · Cited by 218
Self-citationPhase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer
Solit, D. B., Ivy, S. P., Kopil, C., Sikorski, R., Morris, M. J., Slovin, S. F., Kelly, W. K., DeLaCruz, A., Curley, T., Heller, G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1863 · Cited by 211
Self-citationThe Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Whitesell, L., Bagatell, R., & Falsey, R. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481787 · Cited by 203
Clarke, P. A., Hostein, I., Banerji, U., Stefano, F. D., Maloney, A., Walton, M., Judson, I., & Workman, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203753 · Cited by 194
Self-citationLlauger, L., He, H., Kim, J., Aguirre, J., Rosen, N., Peters, U., Davies, P., & Chiosis, G. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049012b · Cited by 191
Self-citationEarly tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.
Smith-Jones, P. M., Solit, D. B., Afroze, F., Rosen, N. X., & Larson, S. M. (2006) · PubMed · Cited by 173
Self-citationMünster, P. N., Basso, A., Solit, D., Norton, L., & Rosen, N. (2001) · PubMed · Cited by 173
Self-citationHsp90 Inhibitors Identified from a Library of Novobiocin Analogues
Yu, X. M., Shen, G., Neckers, L., Blake, H., Holzbeierlein, J., Cronk, B., & Blagg, B. S. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0535864 · Cited by 172
Self-citationHsp90: A Novel Target for Cancer Therapy
Solit, D., & Rosen, N. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812068 · Cited by 170
Self-citationHsp90 Selectively Modulates Phenotype in Vertebrate Development
Yeyati, P. L., Bancewicz, R. M., Maule, J., & van Heyningen, V. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0030043 · Cited by 170
Banerji, U., Walton, M., Raynaud, F., Grimshaw, R., Kelland, L., Valenti, M., Judson, I., & Workman, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0518 · Cited by 164
Self-citationATPases as drug targets: learning from their structure
Chène, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd894 · Cited by 163
Validating cancer drug targets
Benson, J. D., Chen, Y.-N. P., Cornell-Kennon, S. A., Dorsch, M., Kim, S., Leszczyniecka, M., Sellers, W. R., & Lengauer, C. (2006) · Nature · doi:10.1038/nature04873 · Cited by 161
Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex
Xu, W., Yuan, X., Xiang, Z., Mimnaugh, E. G., Marcu, M. G., & Neckers, L. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb885 · Cited by 152
Self-citationSharp, S. Y., Prodromou, C., Boxall, K. J., Powers, M. V., Holmes, J. L., Box, G., Matthews, T. P., Cheung, K.-M. J., Kalusa, A., James, K. E., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0149 · Cited by 145
Self-citationDevelopment of Radicicol Analogues
Soga, S., Shiotsu, Y., Akinaga, S., & Sharma, S. V. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481859 · Cited by 143
Price, J. T., Quinn, J. M. W., Sims, N. A., Vieusseux, J., Waldeck, K., Docherty, S. E., Myers, D., Nakamura, A., Waltham, M. C., Gillespie, M. T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4458 · Cited by 142
Maloney, A., Clarke, P. A., Naaby‐Hansen, S., Stein, R. C., Koopman, J.-O., Akpan, A., Yang, A., Zvelebil, M., Cramer, R., Stimson, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2968 · Cited by 140
Self-citationOverview: Translating Hsp90 Biology into Hsp90 Drugs
Workman, P. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481868 · Cited by 139
Self-citationHeat Shock Protein 90 Inhibitors. A Text Book Example of Medicinal Chemistry?
Janin, Y. L. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050759r · Cited by 127
Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation
Koga, F., Xu, W., Karpova, T., McNally, J. G., Baron, R., & Neckers, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604705103 · Cited by 120
Self-citationSanderson, S., Valenti, M. R., Gowan, S. M., Patterson, L., Ahmad, Z., Workman, P., & Eccles, S. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0439 · Cited by 118
Self-citationZhang, L., Fan, J., Vu, K., Hong, K., Brazidec, J. L., Shi, J., Biamonte, M. A., Busch, D. J., Lough, R. E., Grecko, R., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051146h · Cited by 116
Self-citationSharp, S. Y., Boxall, K. J., Rowlands, M., Prodromou, C., Roe, S. M., Maloney, A., Powers, M. V., Clarke, P. A., Box, G., Sanderson, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3473 · Cited by 112
Self-citationHsp90 Inhibitors in the Clinic
Pacey, S., Banerj, U., Judson, I. R., & Workman, P. (2005) · Springer eBooks · doi:10.1007/3-540-29717-0_14 · Cited by 109
Self-citationHeat-shock protein 90 and Cdc37 interact with LKB1 and regulate its stability
Boudeau, J., Deák, M., Lawlor, M. A., MORRICE, N. A., & Alessi, D. R. (2003) · Biochemical Journal · doi:10.1042/bj20021813 · Cited by 98
Mimnaugh, E. G., Xu, W., Vos, M. D., Yuan, X., & Neckers, L. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0019 · Cited by 98
Self-citation17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models
Burger, A. M., Fiebig, H., Stinson, S. F., & Sausville, E. A. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200404000-00011 · Cited by 89
Zheng, F. F., Kuduk, S. D., Chiosis, G., Münster, P. N., Sepp‐Lorenzino, L., Danishefsky, S. J., & Rosen, N. X. (2000) · PubMed · Cited by 81
Self-citationHeat Shock Protein 90 and ErbB2 in the Cardiac Response to Doxorubicin Injury
Gabrielson, K. L., Bedja, D., Pin, S., Tsao, A. L., Gama, L., Yuan, B., & Muratore, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3721 · Cited by 81
Bortezomib as an Antitumor Agent
Roccaro, A. M., Hideshima, T., Richardson, P. G. G., Russo, D., Ribatti, D., Vacca, A., Dammacco, F., & Anderson, K. (2006) · Current Pharmaceutical Biotechnology · doi:10.2174/138920106779116865 · Cited by 79
Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in Cancer
Neckers, L. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777811979 · Cited by 77
Self-citationInhibitors of the HSP90 Molecular Chaperone: Attacking the Master Regulator in Cancer
McDonald, E., Workman, P., & Jones, K. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812004 · Cited by 75
Self-citationNony, P., Gaude, H., Rossel, M., Fournier, L., Rouault, J.-P., & Billaud, M. (2003) · Oncogene · doi:10.1038/sj.onc.1207179 · Cited by 72
AKT and cancer—Is it all mTOR?
Rosen, N., & She, Q. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.001 · Cited by 66
Self-citationLoss of Hsp90 Association Up-Regulates Src-Dependent ErbB2 Activity
Xu, W., Yuan, X., Beebe, K. E., Xiang, Z., & Neckers, L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00899-06 · Cited by 63
Self-citationDiscovery and Development of Purine-Scaffold Hsp90 Inhibitors
Chiosis, G. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812013 · Cited by 62
Identification of new biomarkers for clinical trials of Hsp90 inhibitors
Zhang, H., Chung, D., Yang, Y., Neely, L., Tsurumoto, S., Fan, J., Zhang, L., Biamonte, M. A., Brekken, J., Lundgren, K., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0537 · Cited by 61
Self-citationWorkman, P. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.020 · Cited by 40
Self-citationDimeric ansamycins—A new class of antitumor Hsp90 modulators with prolonged inhibitory activity
Zhang, H., Yang, Y., Zhang, L., Fan, J., Chung, D., Choi, D., Grecko, R., Timony, G. A., Karjian, P. L., Boehm, M. F., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22392 · Cited by 20
Self-citationHardcastle, A., Tomlin, P., Norris, C., Richards, J., Cordwell, M., Boxall, K. J., Rowlands, M., Jones, K., Collins, I., McDonald, E., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0496 · Cited by 13
Self-citation
Cited by
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Targeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
Self-citationHsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891
Self-citationLenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508
Metadata
- Authors
- WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2007-10
- Volume
- 1113
- Issue
- 1
- Pages
- 202-216
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2042985720
- Cited by
- 521
- References
- 88
- FWCI
- 15.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.